China’s rapid economic growth is giving a positive influence on the pharmaceutical industry. General awareness and understanding for healthcare improvement, research investment and science have been spreading over the country. Also the demands for therapeutics to treat cardiovascular disease, diabetes, and AIDS are increasing due to geographical and economical changes in the country.
  In the Chinese biotech industry, there are a mix of two types of companies, one that takes the Western approach (like in the U.S.), and other that are implementing traditional therapeutics (Chinese medicine). Since consumer business is the key market in China, when Chinese biotech companies consider partnering with foreign companies, one of main strategies would be to apply biotechnology to consumer business.
  Also, the ever increasing pharmaceutical R&D cost is becoming a global issue nowadays and major pharmaceutical companies are actively expanding into China for the advantage of low cost R&D, and establishing their own research facilities in the region.
  Low-cost pre-clinical trials are available and the huge population of China makes easy recruitment of subjects, that generates stronger statistical power to the resulting clinical data. Years ago, the IT industry had established a business model to enable low cost technology development in China, and nowadays that model is inherited by pharmaceutical biotech industries.

  Networking is essential to enter the Chinese investment field. Our local representative based in Shanghai has great experience in dealing with multiple international projects and building strong network in China and is also fluent in Chinese, Japanese, and English .

We indirectly invest in the Chinese life science area by managing fund investment.

Xiaoyu Huang
Chief Representative, Shanghai Office, MediBIC Group
Shanghai Office
49F, 268 XiZang, Middle Road,
Raffles City Office Tower, Shanghai, China 200001
TEL: +(86)-21-6340-5001
FAX: +(86)-21-6340-4909
Email info@medibic.com